Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)
This article was originally published in The Pink Sheet Daily
Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.
You may also be interested in...
After FDA abruptly cancelled an advisory committee meeting on the anesthesia injection product in July to review trial site inspection results for a hypersensitivity study, it issues a “complete response” letter indicating site “operational” concerns.
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.